The Continuous Positive Airway Pressure Device (CPAP) has been used as an effective way for the treatment of Obstructive Sleep Apnea. It provides air at positive pressure through a nasal or facial mask, creating a pneumatic splint that keeps the pharyngeal airway open during inspiration and expiration. However, many negative side effects have been reported including reduction in the cerebral blood flow (CBF). Pressure oscillations will be superimposed on the pressure signal produced by the CPAP to reduce its pressure requirement and eliminate some of the side effects. Airway pressure fluctuations stimulate the release of Adenosine Triphosphate (ATP) and may assist in relieving the collapsed airway associated with OSA by oscillating its compliant structure. Clinical trials will be conducted to assess the lung performance under pressure oscillations. Some of the side effects will be assessed, in particular the effect of the new technology on the cerebral blood flow. A computational dynamic model will be developed to assess the general performance characteristics of the new methodology. The new technology will be a platform for several other methodologies to treat respiratory ailments.